Invitrogen Corporation Wins Appeals Court Decision Against Clontech; Clontech’s Reverse Transcriptase (RT) Products Found To Infringe Invitrogen’s Patent

Invitrogen Corporation (Nasdaq:IVGN), a leading life science company providing innovative technologies to support disease research, today announced a favorable decision in its patent infringement lawsuit against Clontech Laboratories, Inc. On appeal from a decision by the U.S. District Court for the District of Maryland, the U.S. Court of Appeals for the Federal Circuit found that the PowerScript products sold by Clontech infringed Invitrogen's U.S. Patent No. 6,063,608. In the decision, the Court of Appeals remanded the case to the district court for further proceedings.